Cannabis Use Disorder, Severe
Conditions
Brief summary
The goal of this experimental study is to test how three weeks of cannabis abstinence impacts threat and reward processing in females with Cannabis Use Disorder. The main questions it aims to answer are: Compared to using cannabis as usual, will cannabis cue reactivity increase throughout three weeks of abstinence from cannabis? Compared to using cannabis as usual, will threat reactivity be elevated at weeks 1 and 2 of abstinence followed by a decrease at week 3 of abstinence? Compared to using cannabis as usual, will non-drug reward reactivity be lower at weeks 1 and 2 of abstinence followed by an increase at week 3 of abstinence? Compared to successful 3-week abstainers, will threat, non-drug reward, and cannabis cue reactivity differ in relapsers? Researchers will compare females with CUD who abstain from cannabis for three weeks to those who continue to use cannabis as usual to see how cannabis abstinence impacts threat and reward processing. Participants will: Be randomly assigned to continue using cannabis as usual or abstain from cannabis for three weeks Visit the lab 6 times over three weeks, followed by a 1-month follow-up lab visit for the participants assigned to the cannabis abstinence condition Complete phone surveys every other day across the three week study period
Interventions
BEHAVIORALContingency management for cannabis abstinence and lab visit attendance
Escalating monetary reinforcement is provided for continuous cannabis abstinence and lab visit attendance across the three week study period.
BEHAVIORALContingency management for lab visit attendance
Escalating monetary reinforcement is provided for lab visit attendance across the three week study period.
Sponsors
Florida State University
Auburn University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 30 Years
Healthy volunteers
No
Inclusion criteria
* \>=5 cannabis use days per week on average over the past 3 months * Female * \>=6 past-year CUD symptoms (must include withdrawal and at least one criterion other than craving must be met within the past 3 months) * \>=20 days of cannabis use over the past 30 days * Positive urinalysis for THC * Cannabis is primary substance of abuse
Exclusion criteria
* Current pregnancy * History of psychotic, seizure, or cardiovascular disorder * Immediate plan to quit cannabis * Current treatment for cannabis use * Current daily psychotropic medication use * Lotion allergy * Positive urinalysis for any drug other than THC * CSRSS \>= 4 * Current moderate (4+ criteria) or severe (6+ criteria) substance use disorder (SUD) other than CUD or nicotine dependence * CBD use \>= 9 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Late Positive Potential | Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up | The Late Positive Potential (neural measure recorded via electroencephalography) will be quantified from \~400 to 3000ms at central-parietal sensors relative to the onset of a cannabis, neutral, unpleasant, or pleasant image. The Late Positive Potential to cannabis vs. neutral and cannabis vs. pleasant will be the primary contrasts of interest. |
| Reward Positivity | Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up | The Reward Positivity (neural measure recorded via electroencephalography) will be quantified from \~200-300ms at frontal-central sensors relative to the onset of monetary win and loss feedback. The win vs. loss contrast will be the primary outcome of interest. |
| Eyeblink Startle Response | Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up | The Eyeblink Startle Response (recorded via EMG sensors) will be quantified as the peak blink amplitude relative to the onset of an auditory startle probe during blocks with predictable shocks, unpredictable shocks, and no threat of shock. The Eyeblink Startle Response during unpredictable shock threat vs. no shock threat will be the primary contrast of interest. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Delta Power | Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up | Delta Power (neural time-frequency measure recorded via electroencephalography) will be quantified as event-related spectral power from 1-3.5Hz at frontal-central sensors relative to the onset of monetary win and loss feedback. The win vs. loss contrast will be the primary outcome of interest. |
| Delta Intertrial Phase Coherence | Baseline, Week 1, Week 2, Week 3, and (for contingency management abstinence group only) One-Month Follow-Up | Delta Intertrial Phase Coherence (neural time-frequency measure recorded via electroencephalography) will be quantified as intertrial phase coherence of 1-3.5Hz oscillations at frontal-central sensors relative to the onset of monetary win and loss feedback. The win vs. loss contrast will be the primary outcome of interest. |
Countries
United States
Outcome results
None listed